Reuters logo
BRIEF-Merck receives complete response letter from the FDA for Tecos study with sitagliptin
April 7, 2017 / 11:47 AM / 5 months ago

BRIEF-Merck receives complete response letter from the FDA for Tecos study with sitagliptin

April 7 (Reuters) - Merck & Co Inc

* Merck receives complete response letter from the U.S. FDA for Tecos study with Sitagliptin

* Merck & Co Inc- Merck is reviewing letter and will discuss next steps with FDA

* Merck & Co- with the applications, co seeking to include data from Tecos in prescribing information of Sitagliptin-containing medicines Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below